OS (Kaplan-Meier) from the VALFRID study as compared with matched (age, stage, WHO performance status, LDH, extranodal manifestations) reference populations from the Swedish Lymphoma Registry. See supplemental Table 3 for summary by group of each variable used. (A) Cohort A: R-CHOP-treated patients between 2000 and 2015. P = .034. (B) Cohort B: R-CHOP-treated patients between 2010 and 2015. P = .028. The 95% CI is shown.